Back

LDL-cholesterol decrease by anti-PCSK9 monoclonal antibodies: systematic review, meta-analysis and meta-regression of randomized controlled trials

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Pharmacology and Pharmacotherapy ePosters Lipid-Lowering Agents ESC Premium Access ESC Congress 2020

About the speaker

Photo
Ms Iris Ma

University Hospital of Tours, Tours (France)

56 More presentations in this session

Presentation thumbnail
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Professor Y. Huo (Beijing, CN)
Abstract Slides
Presentation thumbnail
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Doctor C. Becker (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics
Doctor S. Frechen (Leverkusen, DE)
Abstract Slides
Presentation thumbnail
Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study
Doctor C. Ballantyne (Houston, US)
Abstract Slides
Presentation thumbnail
The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population
Doctor D. Radenkovic (Greater London, GB)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and Pharmacotherapy ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
19 February 2026
thumbnail
Congress Presentation
Drug related metabolites and genetic polymorphisms predict low low-density lipoprotein cholesterol response to atorvastatin treatment in patients with coronary heart disease
28 August 2020
thumbnail
Congress Presentation
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
30 August 2020
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources